Clinical Trials Arena on MSN
BMS to speak with regulators on mid-stage multiple myeloma success
An FDA AdCom voted for a new intermediate endpoint of MRD for accelerated approvals in multiple myeloma in 2024.
Iberdomide, which is being positioned as a successor to Revlimid, will continue in EXCALIBER-RRMM as the study progresses to ...
Clinical Trials Arena on MSN
J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu
"J&J and Protagonist’s oral plaque psoriasis drug bests BMS’ Sotyktu" was originally created and published by Clinical Trials ...
The Global Multiple Myeloma Market is projected to grow from USD 21.78 billion in 2024 to USD 40.41 billion by 2033, at a CAGR of 7.11%. Growth drivers include rising multiple myeloma cases, advances ...
The J&J drug, named Carvykti, is part of a class of personalized, one-time cancer treatments called CAR T, which are made by engineering a patient’s T cells to go after a particular target on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback